Molecular Diagnostics VL

Genetic Counseling in Prostate Cancer - Brittany Szymaniak

Details
Alicia Morgans discusses genetic counseling in GU cancers with Brittany Szymaniak. This conversation includes the challenges, the benefits, the concerns of genetic testing and how this is accomplished in clinical practice for people who have genital urinary malignancies, so prostate cancer, bladder cancer, kidney cancer. They also discuss the family syndromes for men with prostate cancer that shou...

Molecular Genetic Testing in Prostate Cancer - Wassim Abida

Details
Wassim Abida provides a current roadmap for molecular genetic subtyping in prostate cancer with the main goal of targeting the right therapies for progressing patients. The one clear indication for molecular testing at this point is in the identification of MSI-high prostate cancer because pembrolizumab is approved for this indication. Investigational PARP inhibitors (poly (ADP-ribose) polymerase...

Influence of BRCA-2 Mutations on the Natural History and Response to Therapy in Prostate Cancer- Elena Castro

Details
Elena Castro discusses the role of BRCA-2 mutations and the risk of developing prostate cancer. BRCA-2 germline carriers have an increased risk of developing prostate cancer representing a ~30% lifetime rate of developing prostate cancer. Patients with BRCA-2 mutations tend to develop more aggressive prostate cancer and typically present with lymph node involvement or distant metastases. Based on...

DNA Repair Defects in Metastatic Prostate Cancer - Elena Castro

Details
Elena Castro, MD discusses her recent publication in Journal Clinical Oncology on DNA repair defects in prostate cancer. The primary objective of the study was to determine whether mutations in BRCA 1, BRCA 2, ATM and PALB 2 would affect survival in patients diagnosed with mCRPC. A panel of 107 genes was analyzed. Patients who were carrying these mutations, in particular, BRCA2, had shorter surviv...

Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) A Phase II Study - Emmanuel Antonarakis

Details
Emmanuel Antonarakis introduces the Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH). The aim of this Phase II clinical trial is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also ref...

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

Details
(Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Mem...

The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo

Details
Alicia Morgans and Joaquin Mateo discuss mapping the genomic landscape of advanced prostate cancer, and the realization that many patients with advanced forms of prostate cancer have tumors with defects in the repair of DNA damage. And what we observed for the first time is actually that a drug like olaparib, a PARP inhibitor, that has been used in breast or ovarian cancer, were associated to thes...

Circulating Tumor Cells: Ready for Prime Time? - Interview with Howard Scher

Details
Lecture avaiable here: Howard Scher's presentation at APCCC on: Circulating tumor cells: Ready for Prime time? Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Castration Resistant Prostate Cancer: Where are the Questions? - Eleni Efstathiou

Details
Eleni Efstathiou discusses the history of research in the area of castration resistant prostate cancer and reviews where some of the question stand is this disease state. These questions include how to efficiently target in this area and what are the important biomarkers that are being developed. Also, presented is the question of genetic testing and if it should be offered to high risk disease pa...

Perspective on Novel Agents - Including PARP Inhibitors - Christopher Logothetis

Details
Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage